IL
Illinois House Bill HB4055

Illinois 2023-2024 Regular Session

Illinois House Bill HB4055 Compare Versions

OldNewDifferences
1-Public Act 103-0659
21 HB4055 EnrolledLRB103 31972 BMS 60758 b HB4055 Enrolled LRB103 31972 BMS 60758 b
32 HB4055 Enrolled LRB103 31972 BMS 60758 b
4-AN ACT concerning regulation.
5-Be it enacted by the People of the State of Illinois,
6-represented in the General Assembly:
7-Section 5. The Prior Authorization Reform Act is amended
8-by adding Section 77 as follows:
9-(215 ILCS 200/77 new)
10-Sec. 77. Prior authorization for drug therapies for
11-hereditary bleeding disorders. Notwithstanding any other
12-provision of law, a health insurance issuer or a contracted
13-utilization review organization may not require a prior
14-authorization for drug therapies approved by the U.S. Food and
15-Drug Administration for the treatment of hereditary bleeding
16-disorders any more frequently than 6 months or the length of
17-time the prescription for that dosage remains valid, whichever
18-period is shorter.
3+1 AN ACT concerning regulation.
4+2 Be it enacted by the People of the State of Illinois,
5+3 represented in the General Assembly:
6+4 Section 5. The Prior Authorization Reform Act is amended
7+5 by adding Section 77 as follows:
8+6 (215 ILCS 200/77 new)
9+7 Sec. 77. Prior authorization for drug therapies for
10+8 hereditary bleeding disorders. Notwithstanding any other
11+9 provision of law, a health insurance issuer or a contracted
12+10 utilization review organization may not require a prior
13+11 authorization for drug therapies approved by the U.S. Food and
14+12 Drug Administration for the treatment of hereditary bleeding
15+13 disorders any more frequently than 6 months or the length of
16+14 time the prescription for that dosage remains valid, whichever
17+15 period is shorter.
1918
2019
2120
2221 HB4055 Enrolled LRB103 31972 BMS 60758 b